First half of 2016: building momentum through clinical development and new partnerships
Innate Pharma to host European analyst and investor event in London on July 13th 2016
ASCO 2016: Phase I study protocol investigating IPH4102 in cutaneous T-cell lymphomas
Outcome of Annual General meeting of june 2, 2016
Number of shares and voting rights of Innate Pharma as at may 30, 2016
Report and termination of the liquidity contract with Gilbert Dupont
Investor & Analyst Update, New York, May 16th, 2016
First quarter 2016 report
Upcoming investor conferences
Innate Pharma to hold its Annual General Meeting of shareholders on June 2, 2016 and the release of its reference document (in french)
